Technology ID
TAB-2452
Mouse Model of STAT5 for the Drug Screen and the Research of Cancer and Autoimmunity
E-Numbers
E-080-2011-0
Lead Inventor
Leonard, Warren (NHLBI)
Co-Inventors
Lin, Jian-xin (NHLBI)
Applications
Research Materials
Therapeutic Areas
Infectious Disease
Lead IC
NHLBI
ICs
NHLBI
The invention is a STAT5 mutant mouse that can be used in research related to cancer, autoimmunity and infectious diseases as well as drug screening. The mouse model itself has multiple immunological defects resulting in formation of STAT5 dimers but not tetramers.
It reports that only a minority of IL-2-modulated genes is regulated by STAT5 tetramers. Therefore, selectively targeting tetramer formation might be a relatively specific therapeutic tool wherein one could modulate only part of the actions of a cytokine or growth factor, which allows a new therapeutic approach to modulating immune responses, controlling inflammation, and inhibiting tumor growth.
The STAT5 tetramer deficient mouse is an ideal tool to screen for tetramerization inhibitors that can be used for the treatment of cancer, autoimmunity and inflammation in addition to the basic research applications.
It reports that only a minority of IL-2-modulated genes is regulated by STAT5 tetramers. Therefore, selectively targeting tetramer formation might be a relatively specific therapeutic tool wherein one could modulate only part of the actions of a cytokine or growth factor, which allows a new therapeutic approach to modulating immune responses, controlling inflammation, and inhibiting tumor growth.
The STAT5 tetramer deficient mouse is an ideal tool to screen for tetramerization inhibitors that can be used for the treatment of cancer, autoimmunity and inflammation in addition to the basic research applications.
Commercial Applications
- To design and screen tetramerization inhibitors that are potential new drugs for cancer, autoimmunity and transplantation.
- To identify and study a key subset of STAT5A and/or STAT5B-dependent genes without affecting viability is extremely
- To seek a new therapeutic approach to modulating immune responses, controlling inflammation, and inhibiting tumor growth.
Competitive Advantages
- The tetramer-deficient mice of this invention are viable while mice completely lacking expression of Stat5a and Stat5b exhibit perinatal lethality.
- A model for basic research, to study the cancer, autoimmunity, and infectious diseases associated with STAT5 signaling.
Licensing Contact: